Abstract
In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Current Topics in Medicinal Chemistry
Title: Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Volume: 9 Issue: 8
Author(s): Michael K. Ameriks and Jennifer D. Venable
Affiliation:
Keywords: PI3K, inflammation, allergy, asthma, rheumatoid arthritis, COPD
Abstract: In recent years, pharmaceutical companies have increasingly focused on phosphoinositide 3-kinases delta (PI3Kδ) and gamma (PI3Kγ) as therapeutic targets for the treatment of inflammatory and autoimmune diseases. All class 1 PI3-kinases (α/β/γ/δ) generate phospholipid second messengers that help govern cellular processes such as migration, proliferation, and apoptosis. PI3K δ/γ lipid kinases are mainly restricted to the hematopoetic system whereas PI3Kα/β are ubiquitously expressed, thus raising potential toxicity concerns for chronic indications such as asthma and rheumatoid arthritis. Therefore, the challenge in developing a small molecule inhibitor of PI3K is to define and attain the appropriate isoform selectivity profile. Significant advances in the design of such compounds have been achieved by utilizing x-ray crystal structures of various inhibitors bound to PI3Kγ in conjunction with pharmacophore modeling and high-throughput screening. Herein, we review the history and challenges involved with the discovery of small molecule isoform-specific PI3K inhibitors. Recent progress in the design of selective PI3Kδ, PI3Kγ, and PI3Kδ/γ dual inhibitors will be presented.
Export Options
About this article
Cite this article as:
Ameriks K. Michael and Venable D. Jennifer, Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ, Current Topics in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/156802609789044434
DOI https://dx.doi.org/10.2174/156802609789044434 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Monocyte Locomotion Inhibitory Factor an Anti-Inflammatory Peptide; Therapeutics Originating from Amebic Abscess of the Liver
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Total Wrist Arthroplasty: New Perspectives
Current Rheumatology Reviews Animal Models of Lung Fibrosis
Current Respiratory Medicine Reviews The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View
Mini-Reviews in Medicinal Chemistry Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets Alternate Strategies of Hsp90 Modulation for the Treatment of Cancer and Other Diseases
Current Topics in Medicinal Chemistry Contribution of Ultrasonography of Hands and Wrists in Early Rheumatoid Arthritis
Current Rheumatology Reviews A Systems Biology Approach for miRNA-mRNA Expression Patterns Analysis in Rheumatoid Arthritis
Combinatorial Chemistry & High Throughput Screening Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Current Medicinal Chemistry Chinese Medicine: A Novel Therapeutic Option for Pancreatic Cancer
Current Signal Transduction Therapy Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Identification of Potential Pleiotropic Genes for Immune and Skeletal Diseases Using Multivariate MetaCCA Analysis
Current Genomics Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Current Pharmaceutical Design